MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, CHRS made $11,571K in revenue. -$35,531K in net income. Net profit margin of -307.07%.

Income Overview

Revenue
$11,571K
Net Income
-$35,531K
Net Profit Margin
-307.07%
EPS
-$0.31
Unit: Thousand (K) dollars
Revenue Breakdown
    • Toripalimab
    • Product And Service Other

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-09-30
Net revenue
11,571 10,254 7,599 70,774
Cost of goods sold
3,721 3,395 2,653 20,741
Research and development
27,252 26,306 24,356 21,676
Selling, general and administrative
24,931 26,039 26,025 34,744
Total costs and expenses
55,904 55,740 53,034 77,161
Loss from operations
-44,333 -45,486 -45,435 -6,387
Interest expense
2,325 2,277 2,150 5,362
Gain (loss) on sale of interest in projects
----1,086
Other income (expense), net
2,141 2,901 187 2,084
Loss from continuing operations before income taxes
-44,517 -44,862 -47,398 -10,751
Net loss from continuing operations
-44,517 -44,862 -47,398 -
Net revenue
10,663 ---
Cost of goods sold
287 ---
Research and development
564 ---
Selling, general and administrative
326 ---
Total costs and expenses
1,177 ---
Income from operations
9,486 ---
Gain on sale transactions, net
-422 ---
Other income (expense), net
-78 ---
Net income (loss) from discontinued operations before income taxes
8,986 ---
Net income from discontinued operations, net of tax (note 6)
8,986 342,629 -9,171 -
Net income (loss)
-35,531 297,767 -56,569 -10,751
Earnings per share, basic
-0.31 2.57 -0.49 -0.09
Earnings per share, diluted
-0.31 2.57 -0.49 -0.09
Weighted average number of shares outstanding, basic
116,229,170 116,077,710 115,857,780 115,210,091
Weighted average number of shares outstanding, diluted
116,229,170 116,077,710 115,857,780 115,210,091
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net revenue$10,663K Income from operations$9,486K Total costs andexpenses$1,177K Net income (loss)from discontinued...$8,986K Other income(expense), net-$78K Gain on saletransactions, net-$422K Selling, general andadministrative$326K Research and development$564K Cost of goods sold$287K Net income (loss)-$35,531K Net income fromdiscontinued operations, net...$8,986K Net loss fromcontinuing operations-$44,517K Loss from continuingoperations before income...-$44,517K Other income(expense), net$2,141K Product And ServiceOther$402K Toripalimab$11,169K Interest expense$2,325K Loss from operations-$44,333K Net revenue$11,571K Total costs andexpenses$55,904K Selling, general andadministrative$24,931K Research and development$27,252K Cost of goods sold$3,721K

Coherus Oncology, Inc. (CHRS)

Coherus Oncology, Inc. (CHRS)